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Understanding the range of putative effects of nucleotide variants on cis-regulatory
elements is of increasing interest for several reasons. It should help to distinguish
disease-causing mutations from linked neutral variations. It might explain some of
the reported allelic imbalance, thus leading to interindividual phenotype variability
such as protein levels. It should greatly advance our understanding of CFTR
transcriptional control.
The aim of this study was to evaluate the functional relevance of a few nucleotide
variants identiﬁed within the untranslated CFTR regions. Some of these nucleotide
variants have been shown to be associated with CF and CBAVD diseases (the 48
C>G variant and the allelic variation at an intronic tetranucleotide microsatellite,
respectively), others have only been identiﬁed in controls (the 99C>T variant).
We report an in-depth in silico characterization of these variants, including RNA
secondary structure analysis. By using basic molecular techniques such as EMSA,
ChIP and luciferase reporter constructs assays, we provide experimental evidence
that the studied nucleotide variants have a substantial impact on the basal rate
of transcription of the CFTR gene. We discuss the importance of mapping and
characterizing genetic variations controlling CFTR gene expression for both clinical
diagnosis and research ﬁelds.
This study should provide a wealth of data for understanding cis-acting elements
variability affecting the CFTR regulation and ultimately pinpointing therapeutic
targets.
Both V.V. and C.B. authors contributed equally to this work.
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Within the CFTR gene, some sequence variations have been shown to affect pre-
mRNA splicing. We are interested in sequence variations located within exons
affecting exon recognition and inclusion. Such events have been described for
exons 12 and 13, where nucleotide substitutions can disrupt exon splicing enhancer
or silencer elements, preventing or favoring the recruitement of splicing factors.
These nucleotide variations affect the amount of full length mRNA, thus reducing
total CFTR protein expression and modulating the severity of the disease.
We aim to identify exonic sequence variations within exons 3, 4 and 5 affecting
exonic splicing enhancers and their associated SR proteins.
We cloned into a splicing reporter minigene (pET01 vector) exons 3, 4 and 5
from DNA of patients bearing either WT or mutated sequences and transfected
them in various cell lines. By bioinformatic analysis, Ser/Arg rich proteins (SFRS)
able to bind to CFTR exonic sequences were identiﬁed. By this approach, we have
unmasked two nucleotide substitutions (R74W and R75Q) as creating an alternative
splicing of exon 3 and points to altered binding of SFRS1 and SFRS6. These results
were conﬁrmed by mRNA analysis from nasal cells of healthy volunteers carrying
R75Q after separation of the PCR product by DHPLC.
The identiﬁcation of nucleotide substitutions affecting exon recognition will give
a better understanding of CFTR RNA processing and will lead to reconsider some
neutral variants as disease-causing, thus improving diagnosis accuracy.
Supported by: This work was supported by public grants from INSERM, EC Grant
NEUPROCF (LSHG-CT-2005–512044) and the French Association “Vaincre la
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CF is the most common autosomal recessive disorder in Caucasians, caused by
mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CF) gene.
Some milder forms of CF are due to the skipping of CFTR exon 9, which results
in an aberrant protein. This skipping is under the control of a polymorphism in
intron 8, which can be bound by the splicing protein TDP-43.
Our aims were to elucidate the antagonist effect previously reported between TDP-
43 and ETR-3 splicing proteins and to look for other regulator(s) of CF exon 9
skipping, which could explain the differences in the observed phenotypes.
We show that ETR-3, which was reported to decrease CFTR exon 9 exclusion,
dramatically increases its exclusion in our minigenes, more strongly than TDP-
43. In addition, CUGBP-1, a structurally close member of the ETR-3 protein, has
the opposite effect on CFTR exon 9 splicing. Hence CUGBP-1 reduces exon 9
exclusion, yet both proteins bind onto the intron 8 polymorphic sequence. We
identiﬁed the protein domain responsible for the opposite effect between ETR-3 and
CUGBP-1 as a domain included between the RNA Recognition Motif 2 (RRM2)
and the RRM3 in the so called Divergent Domain, which shows low sequence
conservation.
As a whole, we describe 2 new splicing regulators of CFTR exon 9, ETR-3 and
CUGBP-1. These factors, like TDP-43, which are implicated in another genetic
disease (Myotonic Dystrophy), can bind intron 8 UG-repeats. The interplay between
each of these factors in different tissues could explain the variability in CFTR exon 9
skipping phenotypes.
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It is well-known that the expression of several genes is altered in CF. However; it is
not known how much of the altered gene expression is a consequence of the CFTR
mutation and how much is due to inﬂammation caused by bacterial over-growth in
CF-airways. The aim of the project was to characterize gene expression differences
between CF and nonCF airway epithelia, derived from human explants. Nasal polyps
from 7 patients (4 CF and 3 nonCF) were used to form airway epithelial spheroids
which were preserved under deﬁned bacterial-free conditions for 14 days. Genes that
are differentially expressed between CF and nonCF samples were identiﬁed by DNA
microarray analysis. The promoters of the affected genes were analyzed for over-
represented transcription factor binding sites in order to identify the transcription
factors regulating the differential expression.
Results: The expression proﬁles of CF vs. nonCF airway epithelial spheroids
showed over 2000 genes up- or down-regulated, by more than 2-fold. Among
these we found several genes involved in the inﬂammatory response: e.g.TNFSF9,
TNFRSF10, GLS, CYP1A1 were up-regulated, and IL8, IL6R, SOCS3 were down-
regulated. Furthermore, we found a signiﬁcant (p< 0.05) over-representation of
NFúb binding sites in the promoter regions of up-regulated genes in CF-spheroids.
Discussion: The spheroid-model is unique for maintaining and analyzing CF
airway epithelium ex vivo in a bacterial-free environment. Our data gives a further
insight into molecular processes involved in CF, and the possibility of an intrinsic
inﬂammation preceding infection, involving activity of NFúb.
Supported by: Danish Cystic Fibrosis Association
